Lakewood-Amedex Biotherapeutics Inc.

corporate_fare Company Profile

Lakewood-Amedex Biotherapeutics Inc.

LABT·NASDAQ·Life Sciences·CIK 0002079272

Lakewood-Amedex Biotherapeutics Inc. is a clinical-stage biotechnology company focused on developing antimicrobial products in the United States. The company's primary offerings include products from its Bisphosphocin class, which are a novel type of antimicrobial agents designed to combat infections by disrupting the membranes of microbes. Additionally, Lakewood-Amedex Biotherapeutics Inc. is developing Nu-3, a topical antimicrobial specifically intended for treating infected diabetic foot ulcers. The company, originally incorporated in 2006, was formerly known as Lakewood-Amedex Inc. and adopted its current name, Lakewood-Amedex Biotherapeutics, Inc., in June 2025. Its headquarters are located in University Park, Florida.

Lakewood-Amedex Biotherapeutics Inc. (NASDAQ:LABT) is a publicly traded company in the Life Sciences sector. Wiseek monitors LABT SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.

Recent high-impact activity:

Nu-3 Shows High Barrier to Resistance, Aligns with Federal Action Plan (2026-07-22)
Nu-3 Gel Clears Preclinical Safety Hurdle, Phase 2a Trial Doses Set (2026-07-15)
Lakewood-Amedex Secures Key Patent for New Bisphosphocin® Antimicrobials (2026-06-22)
Lakewood-Amedex to Execute 1-for-10 Reverse Stock Split Amid Listing Concerns (2026-06-17)
Lakewood-Amedex Announces 1-for-10 Reverse Stock Split to Maintain Nasdaq Listing (2026-06-17)

Dilution Risk

Low risk

Filing-implied dilution signals for LABT, detected from its recent SEC filings · based on capital-structure filings through 2026-06-22.

2 recent capital raises1 shelf registrationreverse split

Massive Dilution Confirmed · Ongoing Going Concern Warning

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with L →

show_chartPrice Chart

Loading chart...

feed LABT - Latest Insights

Filing Type

Date Range

LABT

Jul 22, 2026, 8:02 AM EDT

Source: PR Newswire

Importance Score:

Nu-3 Shows High Barrier to Resistance, Aligns with Federal Action Plan

Price at Filing: $1.88

Real-time Price: $2.01

Change: +$0.130 (+7%)

Market Cap: $3.677M

Sentiment: Positive

View Wiseek Article

LABT

Jul 15, 2026, 8:02 AM EDT

Source: PR Newswire

Importance Score:

Nu-3 Gel Clears Preclinical Safety Hurdle, Phase 2a Trial Doses Set

Price at Filing: $2.69

Real-time Price: $2.01

Change: -$0.680 (-25%)

Market Cap: $3.677M

Sentiment: Positive

View Wiseek Article

LABT

Jun 22, 2026, 8:02 AM EDT

Source: PR Newswire

Importance Score:

Lakewood-Amedex Secures Key Patent for New Bisphosphocin® Antimicrobials

Price at Filing: $0.392

Real-time Price: $2.01

Change: Reverse Stock Split

Market Cap: $3.677M

Sentiment: Positive

View Wiseek Article

LABT

Jun 17, 2026, 1:55 PM EDT

Source: Reuters

Importance Score:

Lakewood-Amedex to Execute 1-for-10 Reverse Stock Split Amid Listing Concerns

Price at Filing: $0.61685

Real-time Price: $2.01

Change: Reverse Stock Split

Market Cap: $3.677M

Sentiment: Negative

View Wiseek Article

LABT

Jun 17, 2026, 11:40 AM EDT

Filing Type: 8-K

Importance Score:

Lakewood-Amedex Announces 1-for-10 Reverse Stock Split to Maintain Nasdaq Listing

Price at Filing: $0.744999

Real-time Price: $2.01

Change: Reverse Stock Split

Market Cap: $3.677M

Sentiment: Negative

View Wiseek Article

LABT

May 27, 2026, 8:02 AM EDT

Source: PR Newswire

Importance Score:

Lakewood-Amedex Expands Global IP Portfolio for Lead Drug Nu-3 with New Patents in Australia, New Zealand

Price at Filing: $0.698

Real-time Price: $2.01

Change: Reverse Stock Split

Market Cap: $3.677M

Sentiment: Positive

View Wiseek Article

LABT

May 26, 2026, 4:06 PM EDT

Filing Type: 424B3

Importance Score:

Lakewood-Amedex Finalizes Highly Dilutive Series C Offering and Conversions, Doubling Share Count Amid Going Concern Warning

Price at Filing: $0.727

Real-time Price: $2.01

Change: Reverse Stock Split

Market Cap: $3.677M

Sentiment: Negative

View Wiseek Article

LABT

May 22, 2026, 5:01 PM EDT

Source: Wiseek News

Importance Score:

Lakewood-Amedex Reports Wider Q1 Losses, ($0.20) EPS and Negative Revenue

Price at Filing: $0.7083

Real-time Price: $2.01

Change: Reverse Stock Split

Market Cap: $3.677M

Sentiment: Negative

View Wiseek Article

LABT

May 22, 2026, 4:55 PM EDT

Filing Type: 10-Q

Importance Score:

Going Concern Warning Persists Amidst Highly Dilutive Financing and Nasdaq Listing

Price at Filing: $0.7022

Real-time Price: $2.01

Change: Reverse Stock Split

Market Cap: $3.677M

Sentiment: Negative

View Wiseek Article

LABT

May 18, 2026, 9:20 AM EDT

Source: Reuters

Importance Score:

Positive Data for Lead Candidate Nu-3 Propels Lakewood-Amedex Towards Phase 2 Trial

Price at Filing: $1.26

Real-time Price: $2.01

Change: Reverse Stock Split

Market Cap: $3.677M

Sentiment: Positive

View Wiseek Article

LABT

May 14, 2026, 4:18 PM EDT

Filing Type: 424B4

Importance Score:

Major Investors & Financial Advisor Resell 9.6M Shares, Company Receives No Proceeds Amidst 'Going Concern' Warning

Price at Filing: $1.98

Real-time Price: $2.01

Change: Reverse Stock Split

Market Cap: $3.677M

Sentiment: Negative

View Wiseek Article

LABT

May 12, 2026, 8:02 AM EDT

Source: PR Newswire

Importance Score:

Lakewood-Amedex Secures CRO for Nu-3 Phase 2 Trial, Advancing Lead Candidate

Price at Filing: $3.16

Real-time Price: $2.01

Change: Reverse Stock Split

Market Cap: $3.677M

Sentiment: Positive

View Wiseek Article

LABT

May 01, 2026, 4:05 PM EDT

Filing Type: S-1

Importance Score:

Selling Stockholders Register Over 9.6M Shares for Resale, Posing Significant Dilution Risk Amidst Going Concern Warning

Price at Filing: $3.27

Real-time Price: $2.01

Change: Reverse Stock Split

Market Cap: $3.677M

Sentiment: Negative

View Wiseek Article

LABT

May 01, 2026, 9:33 AM EDT

Source: Reuters

Importance Score:

Lead Candidate NU-3 Shows Strong Antimicrobial Resistance Data for Diabetic Foot Ulcers

Price at Filing: $4.22

Real-time Price: $2.01

Change: Reverse Stock Split

Market Cap: $3.677M

Sentiment: Positive

View Wiseek Article

LABT

Apr 28, 2026, 4:15 PM EDT

Filing Type: 8-K

Importance Score:

Lakewood-Amedex Appoints Biotech Veteran Dr. Joseph Tucker to Board, Bolstering Capital Markets Expertise

Price at Filing: $3.95

Real-time Price: $2.01

Change: Reverse Stock Split

Market Cap: $3.677M

Sentiment: Positive

View Wiseek Article

corporate_fare Company Profile